

EVUSHELD Access Program Frequently Asked Questions

What is the EVUSHELD Access Program?

The Virginia Department of Health developed the EVUSHELD Access Program to increase access to EVUSHELD, a monoclonal antibody for COVID-19 pre-exposure prophylaxis. The program is intended to support Skilled Nursing Facilities with COVID-19 infection prevention by having a mobile unit visit facilities to administer EVUSHELD to any eligible patients and staff, free of charge. VDH has partnered with Indelible Solutions.

What is EVUSHELD and who is it for?

EVUSHELD is COVID-19 protective measure. It is a COVID-19 monoclonal antibody pre-exposure prophylaxis for moderate to severely immunocompromised patients who may not be able to mount an adequate immune response to COVID-19 vaccination. More information regarding EVUSHELD, including detailed eligibility criteria, can be found on the Healthcare Provider Information sheet [here](#).

How is EVUSHELD administered?

The recommended dose of EVUSHELD is 300mg of tixagevimab and 300mg of cilgavimab, administered as two consecutive intramuscular (IM) injections in the gluteal muscles. Repeat dose is recommended every 6 months and should be timed from the date of the most recent EVUSHELD dose.

Is there an observation period?

The patients will need to be observed for 1 hour after the doses are administered to confirm they do not have a reaction to the drug. The mobile vendor will be responsible for observing the patients after administration is completed. No vital check is needed during the observation period.

Is there a cost for the SNF to participate in the EVUSHELD Access Program?

There is no cost for the SNF to participate in this program.

- **Patient(s) covered by Medicare/Medicaid:** Post treatment administration, the mobile vendor will bill Medicare/Medicaid for administration reimbursement.
- **Patient(s) NOT covered by Medicare/Medicaid:** Post treatment administration, the contractor will bill the VDH Central Office for all patients not covered under Medicare/Medicaid.

Who has VDH contracted with to administer EVUSHELD?

The Virginia Department of Health has contracted with Indelible Solutions to mobilize and administer EVUSHELD to eligible patients in nursing homes. Indelible Solutions is a consulting firm specializing in the advancement of health equity by delivering equity-focused public health, healthcare, and social products and services. Indelible Solutions works with SnapNurse, an on-demand network of nurses. SnapNurse is The EVUSHELD Access Program mobile team will consist of one Nurse Practitioner, Registered Nurse, and Certified Nursing Assistant.

How are eligible patients identified to participate in this program?

Participating SNF's will need to identify patients eligible for EVUSHELD. VDH will provide the *EVUSHELD Eligibility - Diagnosis Code & Medication Quick Guide*, to help facilities identify eligible patients. Once patients have been identified, they will need to be reported on the provided *EVUSHELD Medical Director Approval Form*. This form will then need to be approved and signed by the Medical Director and submitted to the Central Office before we can coordinate the mobile vendor's site visit.

Can SNF staff participate in the program if they qualify?

Yes, if the staff member qualifies for EVUSHELD they would be eligible for treatment. The SNF will need to include the staff member on the *EVUSHELD Medical Director Approval Form* if they wish to receive treatment.

What are the SNF roles/responsibilities?

SNFs will be responsible for identifying any eligible patients and sharing the list along with site visit date options with VDH to ensure swift deployment of the vendor.

Will VDH coordinate with the vendor for the recommended repeat dosing?

This is a short pilot lasting 3 months in length. We encourage the facility to ensure access to EVUSHELD either through their contracted pharmacy or enroll as a COVID-19 therapeutics provider to have EVUSHELD available for when patients are eligible for a repeat dose.

Does the SNF need to do any documentation regarding administration?

Yes, once a SNF has confirmed they will like to participate in the EVUSHELD Access Program they will be emailed a document titled *EVUSHELD Medical Director Approval Form* which they will need to complete before VDH can schedule the vendor visit. The form will need to be

filled out with the list of eligible patients at their facility, signed for approval by the Medical Director, and returned to The VDH Therapeutics Team.

Is there a limit on the supply of EVUSHELD?

Currently, there are no supply constraints, however we do not know if the federal government plans to purchase and make available more EVUSHELD after the fall. Given the parameters around who is eligible to take EVUSHELD, we do not anticipate a high number of orders per facility.

Who is responsible for obtaining patient consent?

The vendor will obtain consent on the day of the site visit. For any patient(s) unable to self-consent, the vendor will contact their power of attorney, as named on the *EVUSHELD Medical Director Approval Form*.

Who should I contact if I am interested in bringing the program to my facility, or with questions about the EVUSHELD Access Program?

Please contact Covid19therapeutics@vdh.virginia.gov with any questions related to the EVUSHELD Access Program.